Founded as Techno Venture Management in 1983 as one of the first venture capital firms in Germany, TVM Capital raised its first venture capital fund in 1984. Headquartered in Munich, TVM Capital built strong representation in North America focussing on transatlantic investment models. In 2010, TVM Capital Healthcare started operations in Dubai and closed its first shari’a compliant private equity fund TVM Healthcare MENA I. In May 2012, TVM Capital Life Science celebrated the start of operations of its new Montreal investment office and the first closing of fund generation VII.

Today, the firm is one of the very few true international private equity and venture capital firms, counting numerous global deals with investments across many continents and countries, and with former portfolio companies listed on stock exchanges in Europe and the U.S. (including NASDAQ, London Stock Exchange, Frankfurt Stock Exchange, NASDAQ Europe and the Swiss Stock Exchange).

1983TVM Capital founded in Germany as Techno Venture Management, opening its first office in Munich.
1984First fund, TVM I, is raised.
1996TVM Capital portfolio company Qiagen is the first German company to go public on NASDAQ. TVM Capital was a lead investor in the company.
2001To offer a higher degree of flexibility to investors, TVM Capital’s fifth fund generation consists of two dedicated industry-specific fund entities — TVM V Life Science Ventures, raised in 2001, and TVM V Information Technology, raised in 2002.
2002TVM Capital surpasses $1 billion in investment funds raised and under management.
2005TVM Capital raises EUR240 million for TVM Life Science Ventures VI to focus on biotech and biopharmaceutical investment opportunities in the U.S. and Europe.
2010TVM Capital Healthcare starts operations in Dubai with a Shari’a compliant fund focussing on private equity investments in healthcare businesses in the Middle East and North Africa region, as well as India.
2012TVM Capital Life Science starts operations in the Montreal investment office. An investor syndicate led by Teralys Capital and pharmaceutical company and strategic partner, Eli Lilly and Company invest US$143 million in the first closing of TVM Life Science Ventures VII, a new fund dedicated to investments in the life sciences sector.
2013TVM Capital announces that its activities in information technology have come to an end, and its investment focus will be exclusively on financing innovation in biopharmaceuticals and medical technologies through its venture capital team based in Munich and Montreal, and investing in innovative and fast growing businesses in the broader healthcare market through its private equity team based in Dubai.

2014TVM Capital announces closing of TVM Life Science Ventures VII at 201,6 Million USD following a new and lean investment approach innovating the process of drug development with high capital efficiency while ensuring quality of research and best-in-class processes.